AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Ovarian Reserve in Premenopausal Breast Cancer

NCT01726322 ·Status: TERMINATED

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

NCT00002580 ·Status: COMPLETED ·Phase: PHASE3

Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

NCT01197456 ·Status: COMPLETED

Premenopausal Endocrine Responsive Chemotherapy Trial

NCT00066807 ·Status: TERMINATED ·Phase: PHASE3

AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer Patients

NCT06313476 ·Status: NOT_YET_RECRUITING

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

NCT00002582 ·Status: COMPLETED ·Phase: PHASE3

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206 ·Status: TERMINATED ·Phase: PHASE1

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

NCT02598557 ·Status: COMPLETED ·Phase: PHASE2

Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer

NCT01114464 ·Status: TERMINATED

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

NCT00316836 ·Status: COMPLETED

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

NCT05364255 ·Status: COMPLETED ·Phase: PHASE1

Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

NCT01030250 ·Status: ACTIVE_NOT_RECRUITING

Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer

NCT04389424 ·Status: UNKNOWN

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099 ·Status: TERMINATED ·Phase: PHASE2

Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging

NCT05700006 ·Status: COMPLETED

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

NCT01758146 ·Status: UNKNOWN ·Phase: PHASE3

Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy

NCT06623903 ·Status: NOT_YET_RECRUITING

Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

NCT07127315 ·Status: COMPLETED

Letrozole in Preventing Breast Cancer in Postmenopausal Women

NCT00090857 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

NCT02532400 ·Status: TERMINATED ·Phase: PHASE3

Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

NCT00256217 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen

NCT00532454 ·Status: TERMINATED ·Phase: PHASE2

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer

NCT02483767 ·Status: COMPLETED ·Phase: PHASE3

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369 ·Status: TERMINATED ·Phase: PHASE2